Transcatheter valve-in-valve tricuspid valve replacement via internal jugular and femoral approaches

Stephanie L. Mick, MD,a Samir Kapadia, MD,b Murat Tuzcu, MD,b and Lars G. Svensson, MD, PhD,a
Cleveland, Ohio

Reoperation purely for right-sided heart failure with tricuspid valve disease carries an increased risk of death. We describe a patient who underwent percutaneous tricuspid valve-in-valve insertion via transfemoral and transjugular approaches.

CASE DESCRIPTION

The patient is an 80-year-old woman with a history of rheumatic heart disease requiring mitral valve replacement 34 years before presentation with a Bjork-Shiley valve. Seven years before presentation, she underwent tricuspid valve replacement with a no. 27 Medtronic Mosaic valve along with a maze procedure and permanent pacemaker implantation. Three years later, she underwent lumpectomy and radiation for breast cancer.

Other history included multiple pulmonary emboli, thoracic outlet syndrome, and neuropathic lower extremity pain with right foot drop. The year before presentation, she began to experience lower extremity edema, ascites, and lack of appetite, and was found to have prosthetic tricuspid valve stenosis and insufficiency. On presentation, she exhibited New York Heart Association functional class IV symptoms, was wheelchair-bound, and unable to undergo exercise testing.

Her echocardiogram showed an ejection fraction of 55%, 2+ tricuspid regurgitation, and severe stenosis with peak and mean gradients of 20 mm Hg and 16 mm Hg with reversal of hepatic systolic flow. Coronary angiography revealed no significant coronary artery disease. Pulmonary function testing demonstrated restrictive dysfunction \([\text{FEV}_1] 0.88 \text{ L, 39% of predicted})\) and severely reduced diffusing capacity of lung for carbon monoxide \((\text{DLCO} 5.24 \text{ mL/min/mm Hg, 25% of predicted})\). Given her advanced age and comorbidities, she was judged to be at excessively high risk to undergo cardiac surgery at multiple institutions and she presented to us for transcatheter intervention.

The procedure was performed under general anesthesia. Our initial approach was via a 7-Fr sheath in the right internal jugular vein. We placed a Berman catheter into the right ventricle and measured a 15-mm Hg tricuspid valve gradient by simultaneous right ventricle-right atrial pressures. The Berman was advanced into the right pulmonary artery and we exchanged the sheath for a 24 Fr Edwards sheath over an Amplatz extra stiff wire. Using fluoroscopy and the post markers on the prosthetic valve as a reference point and transesophageal echocardiography guidance, the valve was deployed during rapid ventricular pacing. The Edwards Sapien valve was seated at the tips of the Mosaic valve posts (Figure 1). On observation over time, it appeared to migrate in the ventricular direction. We did not feel confident about its stability in this position and elected to place a second valve. We were concerned about the risk of dislodging the device on crossing the valve with a second device and took preventive measures by placing a 20/6 Z-med balloon into the RV via the internal jugular sheath to be used...
emergently in the case of impending dislodgement of the first device. Then, via a 24-Fr Edwards sheath the right femoral vein, we placed a second Amplatz extra stiff wire into the right pulmonary artery. We inserted another no. 26 Sapien valve into the Mosaic and Sapien valves (Figure 2) without incident, removed the Z-med balloon, and deployed the valve. After deployment, transesophageal echocardiography confirmed a well-placed and seated valve with minimal tricuspid regurgitation. The tricuspid valve gradient decreased to 2 mm Hg and the central venous pressure, which was 33 mm Hg at the start of the procedure, decreased to 13 mm Hg.

After the procedure, the patient was discharged home with improved functional status, edema, and appetite.

**COMMENT**

The first human percutaneous transcatheter tricuspid valve-in-valve implantation was described by Van Garsse and colleagues using an Edwards Sapien valve and internal jugular access. Since then, transatrial and transfemoral methods have been described as well as the use of the Melody valve in this application. There are still less than 40 cases reported in the literature; tricuspid valve-in-valve implantation is still in its infancy. The femoral approach may be favored in cases of relatively vertically oriented tricuspid valves, however, in general, crossing the valve in this approach is believed to be more technically challenging because of the acute angle the catheter must take from the inferior vena cava through the valve to the right ventricle. We accepted this technical challenge as the risk of embolizing the first Sapien valve warranted prophylactic maneuvers via the internal jugular vein.

Troubleshooting maneuvers during transatrial deployment have been described, however, to our knowledge, this is the first description of valve-in-valve deployment both via the internal jugular and femoral veins, along with the prophylactic insertion of a right ventricular balloon. We believe that it is important to report potential challenges and their management as this technique continues to evolve so that all who perform these procedures can benefit from others’ experience. Since this case we have performed 1 additional successful tricuspid valve-in-valve replacement through the femoral vein.

**References**